Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2
Sienna Biopharmaceuticals Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
Blackrock Silver Drills 5.03 Metres of 750 g/t AgEq and Reports Multiple Thick Mineralized Zones in First Assays from Eastern Expansion Drill Program at Tonopah West
